{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:00:37Z","timestamp":1790200837024,"version":"4.1.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Primary hyperoxaluria type 1 (PH1) is a genetic disorder resulting in overproduction of hepatic oxalate, potentially leading to recurrent kidney stones, nephrocalcinosis, chronic kidney disease, and kidney failure. Lumasiran, the first RNA interference therapeutic approved for infants and young children, is a liver-directed treatment that reduces hepatic oxalate production. Lumasiran demonstrated sustained efficacy with an acceptable safety profile over 12 months in infants and young children (age &amp;lt;6 years) with PH1 in ILLUMINATE-B (clinicaltrials.gov: NCT03905694), an ongoing, Phase 3, multinational, open-label, single-arm study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Here, we report interim efficacy and safety findings from ILLUMINATE-B following 30 months of lumasiran treatment. Eligible patients had an estimated glomerular filtration rate (eGFR) &amp;gt;45\u2005ml\/min\/1.73\u2005m<jats:sup>2<\/jats:sup> if \u226512 months old or normal serum creatinine if &amp;lt;12 months old, and a urinary oxalate to creatinine ratio (UOx:Cr) greater than the upper limit of normal. All 18 patients enrolled in ILLUMINATE-B completed the 6-month primary analysis period, entered an extension period of up to 54 months, and continue to participate in the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At Month 30, mean percent change from baseline in spot UOx:Cr was \u221276%, and mean percent change in plasma oxalate was \u221242%. eGFR remained stable through Month 30. In 14 patients (86%) with nephrocalcinosis at baseline, nephrocalcinosis grade improved at Month 24 in 12; no patient worsened. In the 4 patients without baseline nephrocalcinosis, nephrocalcinosis was absent at Month 24. Kidney stone event rates were \u22640.25 per person-year through Month 30. Mild, transient injection site reactions were the most common lumasiran-related adverse events (17% of patients).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In infants and young children with PH1, long-term lumasiran treatment resulted in sustained reductions in urinary and plasma oxalate that were sustained for 30 months, with an acceptable safety profile. Kidney function remained stable, low kidney stone event rates were observed through Month 30, and nephrocalcinosis grade improvements were observed through Month 24.\n<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:uri>https:\/\/clinicaltrials.gov<\/jats:uri>, identifier NCT03905694.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2024.1392644","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T04:34:27Z","timestamp":1726461267000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial"],"prefix":"10.3389","volume":"12","author":[{"given":"Yaacov","family":"Frishberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Shasha-Lavsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Sas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mini","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Sellier-Leclerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Willey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Gansner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella","family":"Magen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1007\/s00467-013-2444-5","article-title":"Primary hyperoxaluria type 1: practical and ethical issues","volume":"28","author":"Cochat","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1093\/ndt\/gfs078","article-title":"Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment","volume":"27","author":"Cochat","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11832-008-0082-4","article-title":"Skeletal features of primary hyperoxaluria type 1, revisited","volume":"2","author":"El Hage","year":"2008","journal-title":"J Child Orthop"},{"key":"B4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41581-022-00661-1","article-title":"Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope","volume":"19","author":"Groothoff","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1253\/circj.CJ-10-0107","article-title":"Cardiac abnormalities in primary hyperoxaluria","volume":"74","author":"Mookadam","year":"2010","journal-title":"Circ J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.ekir.2022.04.012","article-title":"Improved outcome of infantile oxalosis over time in Europe: data from the OxalEurope registry","volume":"7","author":"Deesker","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.nephro.2016.08.002","article-title":"Clinical spectrum of primary hyperoxaluria type 1: experience of a tertiary center","volume":"13","author":"Soliman","year":"2017","journal-title":"Nephrol Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/ki.2009.435","article-title":"Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome","volume":"77","author":"Harambat","year":"2010","journal-title":"Kidney Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.2215\/CJN.13821119","article-title":"End points for clinical trials in primary hyperoxaluria","volume":"15","author":"Milliner","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s40620-023-01611-1","article-title":"Is withdrawal of nocturnal hyperhydration possible in children with primary hyperoxaluria treated with RNAi?","volume":"36","author":"Biebuyck","year":"2023","journal-title":"J Nephrol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1056\/NEJMra1301564","article-title":"Primary hyperoxaluria","volume":"369","author":"Cochat","year":"2013","journal-title":"N Engl J Med"},{"key":"B12","volume-title":"Primary Hyperoxaluria Type 1","author":"Milliner","year":"1993"},{"key":"B13","doi-asserted-by":"publisher","first-page":"592357","DOI":"10.3389\/fmed.2021.592357","article-title":"Natural history of clinical, laboratory, and echocardiographic parameters of a primary hyperoxaluria cohort on long term hemodialysis","volume":"8","author":"Sas","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1007\/s00467-021-05002-1","article-title":"Long-term complications of systemic oxalosis in children-a retrospective single-center cohort study","volume":"36","author":"Ben-Shalom","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"i9","DOI":"10.1093\/ckj\/sfab232","article-title":"Treatment of primary hyperoxaluria type 1","volume":"15","author":"Gupta","year":"2022","journal-title":"Clin Kidney J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1111\/bcp.14925","article-title":"Therapeutic RNA interference: a novel approach to the treatment of primary hyperoxaluria","volume":"88","author":"Forbes","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"B17","volume-title":"Oxlumo [Summary of Product Characteristics]","year":"2022"},{"key":"B18","volume-title":"Oxlumo [Package Insert]","year":"2022"},{"key":"B19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/21678707.2021.2003779","article-title":"Lumasiran: expanding the treatment options for patients with primary hyperoxaluria type 1","volume":"9","author":"Hulton","year":"2021","journal-title":"Expert Opin Orphan Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1681\/ASN.2021060729","article-title":"Endogenous oxalate production in primary hyperoxaluria type 1 patients","volume":"32","author":"Garrelfs","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.gim.2021.10.024","article-title":"Phase 3 trial of lumasiran for primary hyperoxaluria type 1: a new RNAi therapeutic in infants and young children","volume":"24","author":"Sas","year":"2022","journal-title":"Genet Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00467-022-05684-1","article-title":"Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial","volume":"38","author":"Hayes","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.urology.2009.08.061","article-title":"Twenty-four hour and spot urine metabolic evaluations: correlations versus agreements","volume":"75","author":"Hong","year":"2010","journal-title":"Urology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/0004563214529937","article-title":"The comparability of oxalate excretion and oxalate:creatinine ratio in the investigation of primary hyperoxaluria: review of data from a referral centre","volume":"52","author":"Clifford-Mobley","year":"2015","journal-title":"Ann Clin Biochem"},{"key":"B26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/BF00858966","article-title":"Urinary calcium and oxalate excretion in children","volume":"9","author":"Reusz","year":"1995","journal-title":"Pediatr Nephrol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/S0272-6386(99)70380-X","article-title":"Urinary oxalate and urate to creatinine ratios in a healthy pediatric population","volume":"34","author":"Matos","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.4155\/bio-2022-0227","article-title":"Quantification of oxalate by novel LC-MS\/MS: assay development, validation, and application in lumasiran clinical trials","volume":"15","author":"Clausen","year":"2023","journal-title":"Bioanalysis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/ki.2014.222","article-title":"Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type","volume":"86","author":"Mandrile","year":"2014","journal-title":"Kidney Int"},{"key":"B31","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/adc.66.4.501","article-title":"Urinary oxalate and glycolate excretion and plasma oxalate concentration","volume":"66","author":"Barratt","year":"1991","journal-title":"Arch Dis Child"},{"key":"B32","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/jmedgenet-2014-102529","article-title":"Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria","volume":"51","author":"Frishberg","year":"2014","journal-title":"J Med Genet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2215\/CJN.13831119","article-title":"Primary hyperoxaluria: the patient and caregiver perspective","volume":"15","author":"Lawrence","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2215\/CJN.06820613","article-title":"Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice","volume":"9","author":"Hoyer-Kuhn","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00467-021-05393-1","article-title":"The effect of lumasiran therapy for primary hyperoxaluria type 1 in small infants","volume":"37","author":"M\u00e9aux","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e21673","DOI":"10.7759\/cureus.21673","article-title":"Infantile primary hyperoxaluria type 1 treated with lumasiran in twin males","volume":"14","author":"Aldabek","year":"2022","journal-title":"Cureus"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1111\/ajt.16762","article-title":"Primary hyperoxaluria diagnosed after kidney transplant: a review of the literature and case report of aggressive renal replacement therapy and lumasiran to prevent allograft loss","volume":"21","author":"Stone","year":"2021","journal-title":"Am J Transplant"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.2215\/CJN.14730920","article-title":"Phase 1\/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial","volume":"16","author":"Frishberg","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B39","article-title":"Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial [abstract]","author":"Michael","year":""},{"key":"B40","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1392644\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T09:25:53Z","timestamp":1727774753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1392644\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":40,"alternative-id":["10.3389\/fped.2024.1392644"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1392644","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"article-number":"1392644"}}